Abivax S.A.

NASDAQ:ABVX

Biotechnology

Healthcare
$83.83 -0.61%

-$0.62 today

Market cap
$7.34B
Beta
-0.20
P/E (TTM)
-18.1
EPS (TTM)
-$4.83
52W Low $5.69High $148.83

Volume 1.19M

Average 1.59M

ABVX Short-term Investments

Marketable securities and deposits the company expects to convert to cash within a year.

Abivax S.A.NASDAQ: ABVX

Short-term Investments · Q2 FY2026 · quarter ended Jun 2026

Short-term investments remains negative

Q2 FY2026 short-term investments was €22.69M, compared with €0 a year earlier.

Context

  • Short-term investments amounted to 4.9% of total assets at the end of Q2 FY2026, up 4.9 pp from a year earlier.
  • Short-term investments increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
€22.69M— QoQ
Last fiscal yearDec 2025
€13.69M— YoY
Year agoJun 2025
€0— since
Short-term Investments past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Short-term Investments history

EUR · from the balance sheet

Latest · FY2025
13.69M EUR
Year-over-year change
—
4-year CAGR
+591.2%

Short-term Investments vs competitors

How ABVX compares with its peers on the latest reported figures

  • Peers report in different currencies, so short-term investments is compared through growth and share of total assets rather than absolute size.
  • Short-term investments amounts to 4.9% of total assets for ABVX, versus a peer median of 33.0%.
ABVX Competitors
Short-term Investments for ABVX and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
SYRESpyre Therapeutics, Inc.Sep 2026$989.18M USD+134.8%+218.1%89.9%
RCUSArcus Biosciences, Inc.Jun 2026$552M USD-16.7%-1.9%59.7%
NRIXNurix Therapeutics, Inc.Aug 2026$328.01M USD-6.4%+12.2%27.4%
SNDXSyndax Pharmaceuticals, Inc.Mar 2026$221.17M USD-39.0%-12.1%46.8%
ACRSAclaris Therapeutics, Inc.Mar 2026$76.76M USD+2.4%-25.7%38.6%
AVTXAvalo Therapeutics, Inc.Mar 2026$57.01M USD——57.1%
ANNXAnnexon, Inc.Mar 2026$49.82M USD-70.1%-9.4%18.9%
ANABAnaptysBio, Inc.Mar 2026$37.99M USD-84.3%-41.7%11.5%
ABVXAbivax S.A.Jun 2026€22.69M EUR——4.9%
IMMXImmix Biopharma, Inc.Mar 2026$11.33M USD——11.8%
IVAInventiva S.A.Dec 2025€0 EUR——0.0%
Peer median (excluding ABVX) —-16.7%-9.4%33.0%

Competitors are the stored peer set for ABVX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents60.7M26.95M251.94M144.22M516.47M
Short-term Investments6K09.05M013.69M
Net Receivables8.34M8.32M19.1M15.66M10.49M
Inventory4M0000
Other Current Assets00(1K)00
Total Current Assets75.21M36.18M285.97M170.67M551.01M
Property, Plant & Equipment (Net)93K1.59M877K2.67M2.09M
Goodwill32.75M18.42M18.42M18.42M18.41M
Intangible Assets(647K)6.61M6.6M6.61M6.6M
Long-term Investments214K0124K126K0
Tax Assets00000
Other Non-current Assets2.75M12.75M15.07M6.74M5.98M
Total Non-current Assets35.15M39.36M41.09M34.56M33.08M
Total Assets109.23M75.54M327.06M205.23M584.09M
Account Payables18.56M15.48M47.22M43.82M37.55M
Short-term Debt10.06M29.49M30.88M42.84M28.46M
Tax Payables88K86K2.38M4.71M0
Deferred Revenue162K133K52K00
Other Current Liabilities(385K)2.87M3.51M532K(15.91M)
Total Current Liabilities32.26M51.46M88.12M92.83M62.99M
Long-term Debt40.27M8.29M26.62M52.16M30.22M
Deferred Tax Liabilities00005.85M
Deferred Revenue (Non-current)00000
Other Non-current Liabilities10.37M7.77M16.15M18.22M29.46M
Total Non-current Liabilities51.03M16.89M42.94M71.81M66.09M
Total Liabilities83.3M68.36M131.05M164.64M129.08M
Common Stock168K223K629K633K784.67K
Retained Earnings(81.81M)(143.51M)(282.95M)(438.88M)(738.17M)
Accumulated OCI1K302.03K112K(75K)2.31M
Other Stockholders Equity00000
Minority Interest00000
Total Equity25.93M7.19M196.01M40.58M455.01M
Total Debt51.65M39.16M58.04M97.36M45.89M
Net Debt(9.05M)12.21M(193.9M)(46.86M)(470.58M)

Abivax S.A.

NASDAQ:ABVX

Intrinsic Alpha fair value

Locked

Current Price

$83.83

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.